Consistent with a post-hoc analysis of the IMbrave150 trial where tumor and immune cell PD-L1 expression was not found to be associated with survival outcomes after atezolizumab plus bevacizumab in HCC, our proteomic analysis also did not find a relationship between tumor response to bavituximab plus pembrolizumab and PD-L1/2 expression in tumor or immune cells35. This evidence concerns the gene CD274 and neoplasm.